Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
| ▸ | AR | P10275 | 2/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1116603 | 0.91 | GRM5 (0.77) | GRM5L3MBTL1KMT2AMEN1CCR3 | |
| SCHEMBL15962709 | 0.85 | GRM5 (0.69) | GRM5L3MBTL1KMT2AMEN1CCR3 | |
| SCHEMBL23573558 | 0.85 | GRM5 (0.69) | GRM5L3MBTL1KMT2AMEN1CCR3 | |
| SCHEMBL23573560 | 0.85 | GRM5 (0.69) | GRM5L3MBTL1KMT2AMEN1CCR3 | |
| SCHEMBL13294374 | 0.84 | GRM5 (0.81) | GRM5L3MBTL1KMT2AMEN1HTR2B | |
| SCHEMBL3462086 | 0.84 | GRM5 (0.71) | GRM5L3MBTL1KMT2AMEN1CCR3 | |
| SCHEMBL1848094 | 0.83 | CRHR1 (0.75) | GRM5KMT2AMEN1CCR3AR | |
| SCHEMBL13493595 | 0.83 | CRHR1 (0.75) | GRM5KMT2AMEN1CCR3AR | |
| SCHEMBL1848093 | 0.83 | CRHR1 (0.75) | GRM5KMT2AMEN1CCR3AR | |
| SCHEMBL10144674 | 0.82 | GRM5 (0.64) | GRM5L3MBTL1KMT2AMEN1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20160171150-A1 | Chemical Modulators of Pro-Apoptotic BAX and BCL-2 Polypeptides | DANA-FARBER CANCER INSTITUTE, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20160171150-A1 | Chemical Modulators of Pro-Apoptotic BAX and BCL-2 Polypeptides | DANA-FARBER CANCER INSTITUTE, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20110218155-A1 | CHEMICAL MODULATORS OF PRO-APOPTOTIC BAX AND BCL-2 POLYPEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218155-A1 | CHEMICAL MODULATORS OF PRO-APOPTOTIC BAX AND BCL-2 POLYPEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | GRM5 3808/4885L3MBTL1 1339/4885KMT2A 3471/4885 |
| US-20110218155-A1 | CHEMICAL MODULATORS OF PRO-APOPTOTIC BAX AND BCL-2 POLYPEPTIDES | BAX, BCL2, BCL2L1 | GRM5 3259/4885L3MBTL1 505/4885KMT2A 3136/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | GRM5 4583/4885L3MBTL1 772/4885KMT2A 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.